Compare AU
Compare CURE vs. WRLD
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the BetaShares Managed Risk Global Share Fund (Managed Fund) (WRLD). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | WRLD | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 83 | 3 |
Median incremental investment | $619.50 | $2,002.75 |
Median investment frequency | Monthly | Quarterly |
Median total investment | $1,475.04 | $2,718.30 |
Average age group | > 35 | 26 - 35 |
Key Summary
CURE | WRLD | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | WRLD.AX was created on 2015-12-16 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to provide exposure to a broadly diversified portfolio of global shares, whilereducing the volatility of the equity investment returns and defending against losses in decliningmarkets. |
Top 3 holdings | Natera Inc (3.33 %) Incyte Corp (2.95 %) Gilead Sciences Inc (2.81 %) | APPLE INC (5.30 %) MICROSOFT CORP (5.02 %) NVIDIA CORP (4.56 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Other (29.91 %) Information Technology (23.98 %) Health Care (8.49 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | United States (71.69 %) Japan (6.93 %) United Kingdom of Great Britain and Northern Ireland (3.99 %) |
Management fee | 0.45 % | 0.54 % |
Key Summary
CURE | WRLD | |
|---|---|---|
Issuer | Global X | BetaShares |
Tracking index | S&P Biotechnology Select Industry | |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.54 % |
Price | $52.68 | $20.91 |
Size | $36.301 million | $52.727 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.24 % | 1.79 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 21/12/2015 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | WRLD | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 83 | 3 |
Median incremental investment | $619.50 | $2,002.75 |
Median investment frequency | Monthly | Quarterly |
Median total investment | $1,475.04 | $2,718.30 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
CURE | WRLD | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | WRLD |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |